Table 1.

Clinicopathological data

Parameter	WLC (n = 20)	BLC (n = 20)	p valuea
Median time from TURBT to RC, d (IQR)	38 (33–46)	38 (31–48)	0.6
Sex, n (%)			0.3
Female	4 (20)	7 (35)
Male	16 (80)	13 (65)
Smoking, n (%)			0.7
Yes	4 (20)	6 (30)
Former	13 (65)	10 (50)
No	3 (15)	4 (20)
Median age at TURBT, yr (IQR)	71 (69–77)	75 (67–76)	>0.9
T stage at TURBT, n (%)			0.057
T1/T1a/T1b	6 (30)	12 (60)
T2/T2a/T2b	14 (70)	8 (40)
High grade at TURBT, n (%)	20 (100)	20 (100)
Carcinoma in situ at TURBT, n (%)	3 (15)	7 (35)	0.14
Histotype at TURBT, n (%)			>0.9
Pure urothelial carcinoma	16 (80)	16 (80)
Mixed urothelial carcinoma	4 (20)	4 (20)
T stage at RC, n (%)			0.2
T1/T1a/T1b	3 (15)	7 (35)
T2/T2a/T2b	5 (25)	8 (40)
T3/T3a/T3b	9 (45)	3 (15)
T4/T4a	3 (15)	2 (10)
High grade at RC, n (%)	20 (100)	20 (100)
Carcinoma in situ at RC, n (%)	9 (45)	8 (40)	0.7
Histotype at RC, n (%)			0.7
Papillary urothelial carcinoma	0 (0)	1 (5.0)
Pure urothelial carcinoma	17 (85)	15 (75)
Mixed urothelial carcinoma	3 (15)	4 (20)
No tumor	0 (0)	0 (0)
N stage at RC, n (%)			0.13
N0	13 (65)	18 (90)
N+	7 (35)	2 (10)
M stage at RC, n (%)			>0.9
M0	19 (95)	20 (100)
M+	1 (5.0)	0 (0)
Recurrence after RC, n (%)	9 (47)	3 (15)	0.029
Unknown	1	0
Systemic treatment after RC, n (%)b	6 (30)	2 (10)	0.2
Survival, n (%)			0.017
Alive	11 (55)	16 (80)
Died from bladder cancer	9 (45)	2 (10)
Died from other cause	0 (0)	2 (10)
Median follow-up, d (IQR)	580 (280–718)	1780 (1529–2634)	<0.001

WLC = white light cystoscopy; BLC = blue light cystoscopy; TURBT = transurethral resection of bladder tumor; RC = radical cystectomy; IQR = interquartile range.

^aPearson’s χ² test, Wilcoxon rank-sum test, or Fisher’s exact test, as appropriate.

^bPatients receiving chemotherapy or immunotherapy (PD-1 or PD-L1 inhibitor) because of recurrence.